Bimzelx (bimekizumab-bkzx) / UCB, BioRay Biopharmaceutical - LARVOL DELTA

Comparative Pancreatitis Safety Signal of IL-17 Versus IL-23 Inhibitors: A FAERS Pharmacovigilance Study (ACG 2026) - "Reports containing the preferred term âpancreatitisâ were identified for IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab) and IL-23 inhibitors (guselkizumab, risankizumab, tildrakizumab). 707 cases of pancreatitis were reported. Among IL-17 inhibitors, 385 reports were associated with secukinumab, 43 with ixekizumab, and 19 with bimekizumab. Secukinumab demonstrated a significant disproportionality signal [ROR 1.379 (95% CI 1.248â1.525); PRR 1.378; ϲ 39.8; p< 0.05]."

Adverse events • Clinical • Immunology • Inflammation • Inflammatory Arthritis • Pancreatitis • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies • IL17A • IL23A • ROR1

Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review. (PubMed, Front Pharmacol) - "TNF inhibitors (adalimumab, infliximab, etanercept, golimumab, certolizumab pegol) typically achieve Assessment of Spondyloarthritis International Society 40% improvement (ASAS40) rates of 40%-58% at 12-24 weeks versus 13%-24% with placebo, and maintain clinical benefit in many patients over 5-8 years. IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab, brodalumab, netakimab) yield broadly similar ASAS40 responses (30%-50% versus 10%-20% placebo) and are particularly useful in patients with concomitant psoriasis with substantially reduced risk of tuberculosis reactivation. JAK inhibitors (tofacitinib, upadacitinib) represent the newest class, offering oral administration with ASAS40 responses of 40%-52% versus 13%-26% for placebo in both biologic-naïve and biologic-experienced AS, though cardiovascular safety considerations necessitate careful patient selection. Therapeutic selection should consider comorbidities (uveitis favors TNF monoclonal antibodies;..."

Journal • Review • Ankylosing Spondylitis • Back Pain • Cardiovascular • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Musculoskeletal Pain • Ocular Inflammation • Oncology • Ophthalmology • Pain • Psoriasis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Tuberculosis • Uveitis • IL17A

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: NYU Langone Health | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2027 ➔ Jan 2028 | Initiation date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Sep 2027 ➔ Jan 2028

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Orthopedics • Psoriatic Arthritis • Rheumatology

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio study): An International, Pragmatic, Multicentre, Randomised, Controlled, Non-Inferiority Trial. (PubMed, Lancet Reg Health Eur) - P4 | "Patients with stable low disease activity on registered dosages of IL17i (secukinumab, ixekizumab, bimekizumab, brodalumab) or IL23i (guselkumab, risankizumab, tildrakizumab) were eligible. Disease-activity guided, stepwise interval prolongation of IL17i and IL23i in patients with controlled psoriasis is an effective and safe strategy to reduce unnecessary exposure to these expensive drugs. ZonMw (the Netherlands Organization for Health Research and Development), KCE Trials (the Belgian Health Care Knowledge Centre)."

Head-to-Head • Journal • Dermatology • Immunology • Psoriasis • IL17A

Risk of Incident Inflammatory Bowel Disease Among Patients With Psoriasis Treated With IL-17 Versus TNF Inhibitors: A Propensity-Matched TriNetX Study (ACG 2026) - "Adults (â¥18 years) with psoriasis initiating an IL-17 inhibitor (secukinumab, ixekizumab, brodalumab, or bimekizumab) were compared with those starting a TNF inhibitor (adalimumab, infliximab, golimumab, or certolizumab pegol) after diagnosis...Cohorts underwent 1:1 propensity score matching on age, sex, race, ethnicity, diabetes, obesity, celiac disease, tobacco use, psoriatic arthritis (a disease-severity marker), and NSAID, antimicrobial, glucocorticoid, and methotrexate use, yielding 20,547 patients per cohort... After excluding prior IBD, 20,368 IL-17 and 18,987 TNF inhibitor users remained. At 1 year, incident IBD occurred in 46 IL-17 versus 79 TNF users (0.2% vs 0.4%), with significantly lower risk for IL-17 (relative risk [RR] 0.54, 95% CI 0.38â0.78; hazard ratio [HR] 0.56, 95% CI 0.39â0.81; log-rank p=0.002). At 3 years, IBD occurred in 85 versus 161 patients (0.4% vs 0.8%; RR 0.49, 95% CI 0.38â0.64; HR 0.54, 95% CI 0.42â0.70;..."

Clinical • Celiac Disease • Crohn's disease • Dermatology • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Nicotine Addiction • Obesity • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL17A

Bimekizumab as an Effective Treatment in Darier Disease: Clinical Outcomes of a Single-Center Retrospective Analysis of Patients Treated with Biologics. (PubMed, Dermatol Ther (Heidelb)) - "In summary, these real-world data indicate that bimekizumab may be a beneficial and relatively safe treatment option in DD."

Clinical data • Journal • Retrospective data • Dermatology • Immunology • Inflammation • IL17A

Hidradenitis Suppurativa from Preconception to Lactation: Clinical Treatment Decision-Making Review. (PubMed, Dermatol Ther (Heidelb)) - "Topical clindamycin, benzoyl peroxide, chlorhexidine, and selected beta-lactam antibiotics appear to represent preferred options for mild disease or acute flares, whereas tetracyclines, retinoids, spironolactone, apremilast, Janus kinase inhibitors, and most glucagon-like peptide-1 (GLP-1) receptor agonists require avoidance or discontinuation because of fetal or neonatal safety concerns. Among biologics, tumor necrosis factor-α inhibitors remain the best-characterized agents, with certolizumab pegol offering minimal placental transfer and adalimumab or infliximab requiring individualized decisions regarding continuation and timing of discontinuation. Evidence for newer agents, including secukinumab and bimekizumab, is evolving but remains more limited. The review also highlights the importance of preconception counseling, medication transition, multidisciplinary delivery planning, postpartum flare prevention, breastfeeding-compatible therapy, and individualized..."

Journal • Review • Dermatology • Hidradenitis Suppurativa • Immunology • Oncology • Women's Health

Bimekizumab-associated eyelid dermatitis in psoriasis: a real-world clinical case series. (PubMed, Eur J Dermatol) - No abstract available

Journal • Real-world evidence • Dermatitis • Dermatology • Immunology • Psoriasis

Risks of breast or prostate cancer recurrence and a second cancer in patients with inflammatory arthritis following treatment with biologic and targeted synthetic DMARDs - A nationwide cohort study (EULAR 2026) - "Eligible drugs included all five TNFi, non-TNFi bDMARDs (abatacept, rituximab, sarilumab, tocilizumab (for RA), sekukinumab, ixekizumab, bimekizumab (for SpA/PsA), and tsDMARDs, that is JAK inhibitors (baricitinib, filgotinib, tofacitinib, upadacitinib). The corresponding analyses of non-TNFi-bDMARDs, and in particular tsDMARDs, were limited by few events. The findings are clinically reassuring, supporting the safety of TNFi when treating IA in patients with a prior breast or prostate cancer."

Clinical • Ankylosing Spondylitis • Breast Cancer • Genito-urinary Cancer • Immunology • Inflammatory Arthritis • Oncology • Prostate Cancer • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Solid Tumor • Spondylarthritis

When anti-tumor necrosis factor-α backfires: paradoxical psoriasis and psoriatic arthritis in a patient with hidradenitis suppurativa. (PubMed, Dermatol Reports) - "Recently, interleukin (IL)-17 inhibitors (secukinumab, bimekizumab) were also approved in Europe for moderate-to-severe HS. We report a case of paradoxical inverse psoriasis and suspected early psoriatic arthritis induced by adalimumab in an HS patient, successfully managed by switching to secukinumab."

Journal • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • TNFA

Comparative Efficacy and Therapeutic Selectivity of Bimekizumab, Secukinumab, and Adalimumab in Moderate-to-Severe Plaque Psoriasis: A Systematic Review (EADV 2026) - No abstract available

Clinical • Review • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Bimekizumab Associated Pemphigus Vulgaris after Treatment for Psoriasis Vulgaris: A Case Report (EADV 2026) - No abstract available

Case report • Clinical • Dermatology • Immunology • Pemphigus Vulgaris • Plaque Psoriasis • Psoriasis

Comparative Durability Of Response After Biologic Withdrawal: A Systematic Review Of Icotrokinra, Nemolizumab, And Bimekizumab Rebound Data. Defining A New "Treatment-Free Remission Probability Score" (EADV 2026) - No abstract available

Clinical • Review

The dichotomy of clinical clearance and psychological burden: a 24-month follow-up of bimekizumab therapy in refractory hidradenitis suppurativa and pyoderma gangrenosum (EADV 2026) - No abstract available

Clinical • Dermatology • Hidradenitis Suppurativa • Immunology • Pyoderma Gangrenosum

Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 3-year multicenter retrospective study (EADV 2026) - No abstract available

Real-world • Real-world evidence • Retrospective data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Bimekizumab for Refractory Darier Disease: Targeting the IL-17 Axis in a Challenging Genodermatosis (EADV 2026) - No abstract available

Dermatology • IL17A

Severe Scalp Psoriasis Exacerbation with Alopecia During Bimekizumab Therapy: A Diagnostic Dilemma (EADV 2026) - No abstract available

Alopecia • Dermatology • Immunology • Psoriasis

Bimekizumab inhibited radiographic progression across baseline subgroups in biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase 3 study and its open-label extension (EADV 2026) - No abstract available

Clinical • P3 data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Bimekizumab demonstrated sustained improvements in pain and fatigue in patients with axial spondyloarthritis achieving early control of disease activity: 3-year results from two phase 3 studies and their open-label extension (EADV 2026) - No abstract available

Clinical • P3 data • Ankylosing Spondylitis • Fatigue • Immunology • Pain • Seronegative Spondyloarthropathies • Spondylarthritis

HiSCR100 as the New Benchmark. A Critical Meta-Analysis of the Gap Between Statistical Significance and Complete Disease Resolution in Contemporary Hidradenitis Suppurativa Trials (Povorcitinib, Izokibep, Bimekizumab) (EADV 2026) - No abstract available

Retrospective data • Dermatology • Hidradenitis Suppurativa • Immunology

Bimekizumab efficacy & safety versus risankizumab in patients with active psoriatic arthritis: 24-week results from a head-to-head, multicentre, randomised, phase 3b study (BE BOLD) (EADV 2026) - No abstract available

Clinical • Head-to-Head • P3 data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Bimekizumab treatment in routine clinical care for psoriatic arthritis: Interim observational evidence of patient-reported outcome improvements from the European, multicentre SPEAK study (EADV 2026) - No abstract available

Clinical • Patient reported outcomes • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Bimekizumab time to meaningful improvements in clinical and patient-reported outcomes in patients with psoriatic arthritis: Results from a post hoc analysis of two pooled phase 3 studies (EADV 2026) - No abstract available

Clinical • P3 data • Patient reported outcomes • Retrospective data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Psoriatic onychopathy and bimekizumab (Anti-IL-17A/F): clinical and Ultra High-Frequency Ultrasound (UHFUS) outcomes up to Week 52 — Preliminary results of prospective observational study (EADV 2026) - No abstract available

Clinical • Observational data • Immunology • IL17A

Bimekizumab Reduces Systemic Inflammatory Burden in Moderate-to-Severe Psoriasis: Real-World 52-Week Data from the Italian Landscape PSO Cohort (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis